MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy
| Autor: | Farzaneh Rezazadeh, Kambiz Varmira, Fariba Maleki |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Aptamer
medicine.medical_treatment Pharmaceutical Science 02 engineering and technology Adenocarcinoma digestive system 030226 pharmacology & pharmacy Mice 03 medical and health sciences 0302 clinical medicine Cancer immunotherapy Antigens Neoplasm Cell Line Tumor Neoplasms Drug Discovery Animals Humans Medicine skin and connective tissue diseases neoplasms MUC1 Drug Carriers business.industry Mucin-1 Mucin Cancer Immunotherapy 021001 nanoscience & nanotechnology medicine.disease Xenograft Model Antitumor Assays biological factors digestive system diseases Molecular Imaging Radiation therapy Disease Models Animal Tumor progression Cancer research Molecular Medicine Radiopharmaceuticals 0210 nano-technology business |
| Zdroj: | Molecular Pharmaceutics. 18:1842-1861 |
| ISSN: | 1543-8392 1543-8384 |
| Popis: | Mucin 1 (MUC1) is a large, transmembrane mucin glycoprotein overexpressed in most adenocarcinomas and plays an important role in tumor progression. Regarding its cellular distribution, biochemical features, and function, tumor-related MUC1 varies from the MUC1 expressed in normal cells. Therefore, targeting MUC1 for cancer immunotherapy and imaging can exploit the difference between cancerous and normal cells. Radiopharmaceuticals have a potential use as carriers for the delivery of radionuclides to tumors for a diagnostic imaging and radiotherapy. Several radiolabeled targeting molecules like peptides, antibodies, and aptamers have been efficiently demonstrated in detecting and treating cancer by targeting MUC1. This review provides a brief overview of the current status of developments and applications of MUC1-targeted radiopharmaceuticals in cancer imaging and therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|